Fermentation of MG1363/pSS105 was performed as described previously (20) with minor modifications. Briefly, 5 ml pre-culture was grown at 30°C for 6h in LAB medium with 5% Glucose, 4% di-sodium glycerophosphate and 1µg/ml erythromycin by thawing one vial of frozen RCB. The fermenter (BIOFLO 310, New Brunswick Scientific) containing 1L LAB medium supplemented with 5% glucose, 5 mM cysteine, 0.5 mM cystine and 1 µg/ml erythromycin was inoculated with 0.4 ml pre-culture. After 4 h of inoculation, the fermenter was supplied with 50% glucose continuously at the rate of 8 ml/h to maintain 5% glucose in the medium until end of the fermentation. For the time-course experiment, 10 ml samples were withdrawn and used for analysis. Optical density at 600 nm (OD600) was used to assess cell density.
Cultivation was carried out at 30°C with gentle stirring (150 rpm) for 15–18 h until an OD600 of 12–15 was reached. After 18 h of growth, the bulk cell mass was removed by centrifugation (9,000×g, 4◦C, 30 min). The culture supernatant was concentrated 5-fold and buffer exchanged in buffer A (20 mM HEPES, 5%Glucose, 50 mM Sod. Borate, 10 mM L-arginine, 1 mM EDTA, pH6.5) using a QuixStand Benchtop system (Hollow fiber cartridge with cutoff at 30,000 Da, surface area 1,400 cm2, GE Healthcare, Sweden) followed by filtration through a Nalgene Rapid-Flow Sterile Disposable filter units with PES membrane 0.22 μm pore size.
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.